Skip to content
CancerIndex

Publication

NSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma.

Bo Hu, Jacob T Edwards, Hardik Modi, Jim Gamez, Oscar Echeagaray, Kyle Hess, Yue Ren, Diana Anderson, Marta Larrayoz, Jinyi Zhu, Scott Johnson, Gauri Deb, Diana Jankeel, Preethi Janardhanan, Jim Leisten, Sophie Peng, Andy Christoforou, Nicholas Stong, Celia Fontanillo, Chad C Bjorklund, Patrick R Hagner, Anita K Gandhi, Jose A Martinez-Climent, Rama Krishna Narla, Antonia Lopez-Girona, Mark Rolfe, Neil Bence, Deborah S Mortensen, Lynda Groocock

BloodSep 24, 2026PMID 42371798doi:10.1182/blood.2025031998 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 30, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260930-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

The t(4;14) chromosomal translocation drives overexpression of the histone methyltransferase NSD2 and defines a high-risk segment of patients with multiple myeloma (MM). Herein, we report the discovery of NSD2-ligand-directed degrader (NSD2-LDD), a cereblon-recruiting and PWWP1-mediated LDD that…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.